From Reactive Claims to Population Health: The Strategic Question Most Saudi Insurers Have Not Yet Answered

The Saudi Council of Health Insurance has done something most regulators do not do explicitly. It has named the strategic direction of the reform, identified the conditions that will drive it, and set a timeline. The CHI Population Health Management strategy targets five specific conditions over five years: diabetes, hypertension, obesity, coronary heart disease, and smoking. These are not arbitrary selections. They are the upstream causes of the disease burden that generates 73% of Saudi deaths, the lion's share of inpatient admissions, and a disproportionate share of the claims cost that will reshape insurer loss ratios through the next decade. The strategy is published. The question for each connected insurer and provider is not whether to engage with it. The question is whether the internal capability to do so exists.

The honest answer for most organisations in the Saudi market is no. The reactive claims-based operating model that has served the industry through the fee-for-service period is not the model that the regulator is now moving towards. The shift from paying for episodes after they occur to managing the population conditions that produce them is a different commercial discipline. It requires different data, different analytical capability, different clinical partnerships, and different financial measurement. None of these is automatic. All of them are scarcer in the Saudi market than the strategic direction implies.

What the CHI Strategy Actually Names

The five-condition PHM strategy is more analytically loaded than the headline suggests. Each of the conditions is chosen because it is causally upstream of the conditions that drive the highest reimbursement volume. Diabetes drives renal disease, cardiovascular events, and amputation. Hypertension drives stroke, heart failure, and cardiovascular disease more broadly. Obesity drives diabetes and cardiovascular disease, and increasingly cancer. Coronary heart disease is the immediate cause of approximately 37% of Saudi deaths. Smoking is the single most modifiable risk factor across all four of the others.

The selection is therefore a precision strategy disguised as a population strategy. The CHI is identifying the five points in the disease pathway where intervention has the highest leverage on total system cost. An insurer that successfully reduces diabetes incidence by even a small percentage in its book is not just preventing diabetes claims. It is preventing the entire downstream chain of cardiovascular events, hospitalisations, dialysis episodes, and specialty drug spending that diabetic patients accumulate over decades.

The Multimorbidity Reality

If 26.7% of the Saudi adult population has multiple concurrent NCDs, and that rate rises to 62.9% in the population aged 65 and over, then the operational unit of analysis for PHM is not the individual disease. It is the multimorbid patient. The hypertensive diabetic with hyperlipidemia is not five times more expensive than three single-condition patients added together. The interaction effects (drug interactions, contraindications, hospital readmission risk, polypharmacy) compound. The PHM programme that targets each of the five CHI conditions in parallel rather than as an integrated multimorbid patient population is structurally less effective than its design implies.

This has direct architectural consequences for insurers. The disease management programme is the wrong unit. The chronic condition cohort is the wrong unit. The right unit is the multimorbid patient population, segmented by risk stratification that reflects the actual compounding effect of co-occurring conditions. NPHIES data supports this segmentation. Most insurers are not yet performing it.

Three Capabilities That Distinguish Real PHM from Performative PHM

Population Health Management, as a discipline, is not the same as disease management, case management, wellness programme, or member engagement. Each of these is a component. None on its own constitutes PHM. The distinction matters because performative PHM is significantly easier to launch than real PHM, and the Saudi market is now seeing significant volumes of the former.

The first capability is risk-stratified cohort identification. A real PHM programme does not target every diabetic in the book. It targets the diabetic cohort whose claims trajectory, comorbidity profile, and prescribing pattern indicate escalating risk over the next twelve to twenty-four months. That identification requires NPHIES longitudinal analysis at the individual patient level, with prescribing patterns, utilisation history, and laboratory result tracking integrated. Most Saudi insurers do not have this analytical infrastructure today, although the data to build it exists in NPHIES.

The second capability is integrated clinical pathway management. Once a patient is identified as high-risk, the question is who manages them: the insurer care manager, the network primary care provider, the disease-specific specialist, or some combination. A real PHM programme has documented care coordination protocols, defined accountability for which provider role does what at each stage, and structured handoffs supported by clinical record sharing. A performative PHM programme has a care manager calling patients to remind them about appointments.

The third capability is financial measurement against a defensible baseline. The return on a PHM programme is the avoided cost of acute utilisation that would otherwise have occurred. Without a credible counterfactual baseline (what would the cohort have cost without intervention), the savings number is unverifiable. Many published PHM programme results worldwide cannot withstand actuarial scrutiny because the baseline is constructed retrospectively rather than from comparable cohorts under standardised methodology. Insurers reporting PHM impact need to be able to defend the analytical method, not just the outcome number.

The NPHIES Connection and the Reform Convergence

The NPHIES platform provides the data foundation for credible PHM at scale. Longitudinal patient-level utilisation, diagnosis history, prescribing patterns, and provider interaction sequences are present in the transaction record. The Alghnam et al. analysis published in Annals of Saudi Medicine in 2024 demonstrates the feasibility: using machine learning on electronic health records from a cohort of approximately 650,000 Saudi patients, the researchers produced higher-resolution NCD prevalence estimates than previously available national figures, and quantified multimorbidity patterns at the level of disease cluster combinations.

The methodology is replicable at insurer scale. What it requires is the analytical capability discussed in our NPHIES maturity analysis, applied specifically to the PHM use case. Insurers operating at NPHIES Level 1 or Level 2 cannot generate the risk-stratified cohort identification that real PHM requires. Insurers operating at Level 3 or Level 4 can.

The convergence with the broader reform environment makes this particularly consequential. The AR-DRG transition means that the financial reward for preventing an admission is now retained at the insurer level rather than passed to the provider as additional revenue. The NISS expansion to 23 million beneficiaries adds population without expanding inpatient capacity, making prevention more important. The Insurance Authority's RBC framework will incorporate the chronic disease risk profile of the insured book into capital adequacy calculations. The CHI's published PHM strategy creates regulatory direction. All four reforms point at the same operational capability: the ability to identify, stratify, and intervene on chronic disease risk before it becomes acute claims volume.

What This Looks Like in Practice

A practical PHM implementation in a Saudi insurer book starts with a quantified diagnosis of the existing population. How many beneficiaries have one of the five CHI-target conditions? How many have two or more? What is the actuarial profile of those cohorts in terms of utilisation trajectory, admission risk over twelve and twenty-four months, and pharmaceutical exposure? Which provider relationships are appropriately structured for cohort-based clinical management, and which would need to be rebuilt?

The next stage is structured pilot deployment on the highest-leverage cohort. The most analytically defensible starting point is typically uncontrolled diabetes with at least one cardiovascular comorbidity. The cohort is identifiable from NPHIES, the clinical evidence for intervention is robust, the cost impact is large, and the timeline to outcome is short enough to support a meaningful pilot evaluation.

The third stage is the operational and financial infrastructure that turns a successful pilot into a programme: care management workflow, clinical record integration with network providers, outcome measurement and reporting cadence, contracting evolution towards outcome-based reimbursement where appropriate, and board-level governance over PHM as a distinct discipline. This is where most performative PHM stops. It is where real PHM begins.

The window for building this is the next twenty-four months. The CHI strategy timeline is five years. The reforms that converge on PHM capability (AR-DRG, NISS, IA RBC) reach full effect in 2027 and 2028. The insurers and providers that build genuine PHM capability now will be operating with structural cost containment advantages through the rest of the decade. The insurers and providers that defer the question will be doing PHM under regulatory and competitive pressure rather than by strategic choice.